U.S. Army Medical Research and Materiel Command (USAMRMC) is conducting market research to assess the availability and technical maturity of technologies for rapid diagnosis of infectious diseases in environments with limited infrastructure support.
Prior to determining an acquisition strategy, USAMRMC will use this Request for Information (RFI) to assess the current state of available technologies and gauge industry interest and commercialization outlook for further development of candidates for the US market.
Prioritized diseases of interest impacting military mission readiness include: dengue, leptospirosis, malaria, meningococcal meningitis and noroviral gastroenteritis. Estimated annual purchase quantities are 5,000 assays for each target.
Specifically, the USAMRMC is interested in determining:
| Candidate diagnostic products, either in the development pipeline or currently marketed in the US or in foreign markets that can be used to diagnose the priority pathogens |
| Current technology status of each candidate |
| FDA clearance status and timelines |
| Available data on device sensitivity, specificity, external controls, power requirements, weight, footprint, time to result, user complexity and storage |
| Level of support interested industry sources would require from the DoD in terms of technical and scientific expertise, clinical sites, and research and development funding |
USAMRMC also requests industry feedback on strategies by which candidate assays can be combined, kitted, or otherwise optimized to reduce logistical burden and provide cost-savings over time.
Further details are available under Solicitation Number: W81XWH13RFIID. The response deadline is May 21, 2013.